Pipothiazine (Piportyl) palmitate and undecylenate. new additions to the depot-neuroleptic group
Gunby, B.
Tidsskrift for den Norske Laegeforening Tidsskrift for Praktisk Medicin Ny Raekke 95(14): 899
1975
ISSN/ISBN: 0029-2001 PMID: 237341 Document Number: 94419
Document emailed within 1 workday
Related Documents
Blanc, M.; Girard, M.; Granier, F.; Escande, M.; Cotonat, J. 1986: Pharmacokinetics of pipothiazine palmitate, after intramuscular administration in schizophrenic patients Therapie 41(1): 27-30Jain, R.C.; Ananth, J.V.; Lehmann, H.E.; Ban, T.A. 1975: A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients Current Therapeutic Research 18(4): 585-589
Bechelli, L.P.; Navas-Filho, F. 1986: Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia L'Encephale 12(3): 121-125
Ereshefsky, L.; Saklad, S.R.; Jann, M.W.; Davis, C.M.; Richards, A.; Seidel, D.R. 1984: Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches Journal of Clinical Psychiatry 45(5 Part 2): 50-59
Lindholm, H.; Ljungberg, L. 1973: Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation Acta Psychiatrica Scandinavica. Supplementum 246: 52-56
Johnson, D.A. 1984: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia Journal of Clinical Psychiatry 45(5 Part 2): 13-21
Belosludtsev, K.N.; Belosludtseva, N.V.; Mironova, G.D. 2008: The role of a mitochondrial palmitate/Ca(2+)-activated pore in palmitate-induced apoptosis Biofizika 53(6): 967-971
Sebestik, V.; Jelínek, J. 1982: Erythrocyte survival and haematocrit values in rats after I.v. application of ethyl palmitate and methyl palmitate emulsions Folia Haematologica 109(4): 608-611
von Schrader, H.W.; Buscher, G.; Dierdorf, D.; Freytag, A.; Mügge, H.; Wolf, D. 1985: Bioavailability and tolerance of xanthinol nicotinate depot preparations. Comparison of a conventional 500 mg xanthinol nicotinate depot tablet with new 500 mg and 1 g depot tablets Arzneimittel-Forschung 35(9): 1468-1472
Sindelár, K.; Metysová, J.; Protiva, M. 1973: A new group of highly potent neuroleptic drugs in the series of 10-piperazi nodibenzo (b,f) thiepins: 8-Acyl derivatives of perathiepin (chemistry and pharmacology) Activitas Nervosa Superior 15(2): 97-98
2009: Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents Prescrire international 18(104): 251
Lavie, C.J.; Olmsted, T.R.; Ventura, H.O.; Lepler, B.J. 1986: Neuroleptic malignant syndrome. An underdiagnosed reaction to neuroleptic agents? Postgraduate Medicine 80(3): 171-178
Pongsatha, S.; Ekmahachai, M.; Chaovisitsaree, S.; Suntornlimsiri, N.; Morakote, N. 2009: Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study Journal of the Medical Association of Thailand 92(10): 1263-1267
Janssen, P.A.; Niemegeers, C.J.; Schellekens, K.H. 1965: Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquillizers) from Animal Data?i. "neuroleptic Activity Spectra" for Rats Arzneimittel-Forschung 15: 104-117
Sippell, W.G.; Partsch, C.J.; Hümmelink, R.; Lorenzen, F. 1994: Long-term therapy of true precocious puberty in girls using Decapetyl-Depot, a superactive gonadoliberin agonist in depot microcapsulated form Ceskoslovenska Pediatrie 49(1): 13-18
Mulley, J.C.; Bryant, G.D.; Sutherland, G.R. 1980: Additions to the exclusion map of man Annales de Genetique 23(4): 198-200
Ross, W.B.; Mohiuddin, S.M. 1983: Antiarrhythmic therapy: new additions and future expectations Geriatrics 38(1): 30-35
Novokhatskiĭ, A.S. 1990: Additions to the theory of the dual nature of photoreception Oftalmologicheskii Zhurnal 2: 104-108
Guénard, B.; Economo, E.P. 2015: Additions to the checklist of the ants (Hymenoptera: Formicidae) of Peru Zootaxa 4040(2): 225-235
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508